|
Insurance & Litigation
•
|
Tools & Information
•
•
•
|
|
 Back to New York Times Health News Archives
New York Times Health News: 12-20-2004
A new program is rooted in the view of autism as an alternative form of brain wiring, rather than a devastating disorder.
Auditors will be sent to investigate techniques used by states to shift hundreds of millions of dollars in Medicaid costs to the U.S. government.
Although advertising will be suspended indefinitely, Pfizer plans to continue marketing Celebrex to doctors.
The F.D.A. said that it would consider whether to remove Iressa, a product from AstraZeneca, from the market after the drug failed to prolong the lives of people in a clinical trial.
Scott and Jill Stimell faced an agonizing choice: they could watch their child die, or pursue a drastic and painful treatment.
The story of COX-2 drugs is an example of how difficult it is for the F.D.A. to monitor the safety of drugs after they have been approved for the market.
|
|
